CNCR
ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR
Delisted
CNCR was delisted on the 27th of May, 2025.
13 hedge funds and large institutions have $1.88M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2023 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Holders
13
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$312K | |
| 2 | +$220K | |
| 3 | +$84K | |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$48.5K |
| 5 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
+$8.05K |
Top Sellers
| 1 | -$283K | |
| 2 | -$151K | |
| 3 | -$128K | |
| 4 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$113K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$47K |